Comments
Loading...

Adaptive Biotechnologies Analyst Ratings

ADPTNASDAQ
Logo brought to you by Benzinga Data
$9.36
0.161.74%
At close: -
$9.30
-0.06-0.64%
After Hours: 4:57 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$13.00
Lowest Price Target1
$6.00
Consensus Price Target1
$9.43

Adaptive Biotechnologies Analyst Ratings and Price Targets | NASDAQ:ADPT | Benzinga

Adaptive Biotechnologies Corp has a consensus price target of $9.43 based on the ratings of 7 analysts. The high is $13 issued by Piper Sandler on May 6, 2025. The low is $6 issued by JP Morgan on August 2, 2024. The 3 most-recent analyst ratings were released by Piper Sandler, Morgan Stanley, and Goldman Sachs on May 6, 2025, May 5, 2025, and May 2, 2025, respectively. With an average price target of $10.67 between Piper Sandler, Morgan Stanley, and Goldman Sachs, there's an implied 14.70% upside for Adaptive Biotechnologies Corp from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Dec 24
1
Jan
1
Feb
1
Mar
2
1
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
2.4
Sell
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Piper Sandler
Morgan Stanley
Goldman Sachs
Scotiabank
BTIG

1calculated from analyst ratings

Analyst Ratings for Adaptive Biotechnologies

Buy NowGet Alert
05/06/2025Buy Now39.78%Piper Sandler
David Westenberg59%
$11 → $13MaintainsOverweightGet Alert
05/05/2025Buy Now-3.23%Morgan Stanley
Tejas Savant50%
$7 → $9MaintainsEqual-WeightGet Alert
05/02/2025Buy Now7.53%Goldman Sachs
Salveen Richter52%
$9 → $10MaintainsBuyGet Alert
03/21/2025Buy Now-3.23%Goldman Sachs
Salveen Richter52%
$8 → $9UpgradeNeutral → BuyGet Alert
02/20/2025Buy Now18.28%Piper Sandler
David Westenberg59%
$7 → $11ReiteratesOverweight → OverweightGet Alert
02/13/2025Buy Now29.03%Scotiabank
Sung Ji Nam44%
$10 → $12MaintainsSector OutperformGet Alert
01/28/2025Buy Now-19.35%Goldman Sachs
Salveen Richter52%
$5.5 → $7.5MaintainsNeutralGet Alert
12/18/2024Buy Now-3.23%BTIG
Mark Massaro71%
$8 → $9MaintainsBuyGet Alert
11/11/2024Buy Now-24.73%Piper Sandler
David Westenberg59%
$6 → $7MaintainsOverweightGet Alert
10/02/2024Buy Now-13.98%BTIG
Mark Massaro71%
$7 → $8MaintainsBuyGet Alert
08/02/2024Buy Now-35.48%JP Morgan
Rachel Vatnsdal65%
$5 → $6MaintainsOverweightGet Alert
05/08/2024Buy Now-46.24%JP Morgan
Rachel Vatnsdal65%
$8 → $5MaintainsOverweightGet Alert
04/04/2024Buy Now-46.24%BTIG
Mark Massaro71%
$6 → $5MaintainsBuyGet Alert
02/16/2024Buy Now-46.24%Goldman Sachs
Salveen Richter52%
$11 → $5MaintainsNeutralGet Alert
02/15/2024Buy Now-13.98%JP Morgan
Rachel Vatnsdal65%
$11 → $8MaintainsOverweightGet Alert
11/13/2023Buy Now-35.48%Piper Sandler
David Westenberg59%
$13 → $6MaintainsOverweightGet Alert
11/10/2023Buy Now18.28%JP Morgan
Rachel Vatnsdal65%
$12 → $11MaintainsOverweightGet Alert
10/24/2023Buy Now7.53%Morgan Stanley
Tejas Savant50%
$13 → $10MaintainsEqual-WeightGet Alert
10/16/2023Buy Now39.78%Piper Sandler
David Westenberg59%
$14 → $13MaintainsOverweightGet Alert
08/08/2023Buy Now50.54%Piper Sandler
David Westenberg59%
$15 → $14MaintainsOverweightGet Alert
08/04/2023Buy Now39.78%Morgan Stanley
Tejas Savant50%
$14 → $13MaintainsEqual-WeightGet Alert
05/05/2023Buy Now50.54%Morgan Stanley
Tejas Savant50%
$15 → $14MaintainsEqual-WeightGet Alert
02/16/2023Buy Now61.29%Morgan Stanley
Tejas Savant50%
$16 → $15MaintainsEqual-WeightGet Alert
02/15/2023Buy Now-24.73%Credit Suisse
Dan Leonard54%
→ $7Reiterates → UnderperformGet Alert
01/05/2023Buy Now61.29%Scotiabank
Sung Ji Nam44%
→ $15Initiates → Sector OutperformGet Alert
12/21/2022Buy Now50.54%Piper Sandler
David Westenberg59%
$7.5 → $14UpgradeNeutral → OverweightGet Alert
11/07/2022Buy Now72.04%Morgan Stanley
Tejas Savant50%
$17 → $16MaintainsEqual-WeightGet Alert
10/26/2022Buy Now-19.35%Piper Sandler
David Westenberg59%
$12 → $7.5MaintainsNeutralGet Alert
08/25/2022Buy Now-13.98%Credit Suisse
Dan Leonard54%
→ $8Initiates → UnderperformGet Alert
08/17/2022Buy Now29.03%Piper Sandler
David Westenberg59%
$7.5 → $12MaintainsNeutralGet Alert
06/03/2022Buy Now-19.35%Piper Sandler
David Westenberg59%
→ $7.5Initiates → NeutralGet Alert
05/24/2022Buy Now7.53%Goldman Sachs
Salveen Richter52%
$14 → $10MaintainsNeutralGet Alert

FAQ

Q

What is the target price for Adaptive Biotechnologies (ADPT) stock?

A

The latest price target for Adaptive Biotechnologies (NASDAQ:ADPT) was reported by Piper Sandler on May 6, 2025. The analyst firm set a price target for $13.00 expecting ADPT to rise to within 12 months (a possible 39.78% upside). 11 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Adaptive Biotechnologies (ADPT)?

A

The latest analyst rating for Adaptive Biotechnologies (NASDAQ:ADPT) was provided by Piper Sandler, and Adaptive Biotechnologies maintained their overweight rating.

Q

When was the last upgrade for Adaptive Biotechnologies (ADPT)?

A

The last upgrade for Adaptive Biotechnologies Corp happened on March 21, 2025 when Goldman Sachs raised their price target to $9. Goldman Sachs previously had a neutral for Adaptive Biotechnologies Corp.

Q

When was the last downgrade for Adaptive Biotechnologies (ADPT)?

A

There is no last downgrade for Adaptive Biotechnologies.

Q

When is the next analyst rating going to be posted or updated for Adaptive Biotechnologies (ADPT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adaptive Biotechnologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adaptive Biotechnologies was filed on May 6, 2025 so you should expect the next rating to be made available sometime around May 6, 2026.

Q

Is the Analyst Rating Adaptive Biotechnologies (ADPT) correct?

A

While ratings are subjective and will change, the latest Adaptive Biotechnologies (ADPT) rating was a maintained with a price target of $11.00 to $13.00. The current price Adaptive Biotechnologies (ADPT) is trading at is $9.30, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch